Retapamulin for Reducing MRSA Nasal Carriage

Trial Profile

Retapamulin for Reducing MRSA Nasal Carriage

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Retapamulin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 25 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top